RIGL - Rigel Pharmaceuticals, Inc.
2.4400 -0.05 (-2.01%)
After hours: 5:05PM EDT
| Previous Close | 2.4900 |
| Open | 2.4700 |
| Bid | 2.0200 x 28000 |
| Ask | 2.4900 x 900 |
| Day's Range | 2.4200 - 2.5000 |
| 52 Week Range | 1.9600 - 3.6500 |
| Volume | 543,615 |
| Avg. Volume | 1,431,156 |
| Market Cap | 416.311M |
| Beta (3Y Monthly) | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3850 |
| Earnings Date | Jul 30, 2018 - Aug 3, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.33 |
- Simply Wall St.•9 days ago
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Are Analysts Optimistic?
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL): Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the...
- Zacks•17 days ago
Rigel Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Rigel Pharmaceuticals, Inc. (RIGL) has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks•21 days ago
Dova Receives Approval for Doptelet in Europe, Stock Up
Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.
- Insider Monkey•24 days ago
Here’s What Hedge Funds Think About Rigel Pharmaceuticals, Inc. (RIGL)
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- PR Newswire•last month
Rigel to Present Two Posters Highlighting Fostamatinib at the 24ᵗʰ Congress of the European Hematology Association (EHA)
SOUTH SAN FRANCISCO , June 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two posters ...
- Motley Fool•last month
Is Rigel Pharmaceuticals a Buy?
The stock rose after a promising full-year 2018 earnings report and then rapidly began sliding back to multiyear lows. What's going on?
- Thomson Reuters StreetEvents•last month
Edited Transcript of RIGL earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Rigel Pharmaceuticals Inc Earnings Call
- PR Newswire•2 months ago
Rigel to Present at Jefferies 2019 Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , May 31, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, is scheduled to present ...
- Zacks•2 months ago
Rigel Initiates Enrollment in Pivotal Blood Disorder Study
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.
- PR Newswire•2 months ago
Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia
SOUTH SAN FRANCISCO, Calif., May 16, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL), today announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of fostamatinib disodium hexahydrate (fostamatinib) in warm antibody autoimmune hemolytic anemia (AIHA). "Enrolling the first patient in our Phase 3 clinical trial of fostamatinib in warm AIHA is an important milestone in our efforts to develop the first FDA-approved therapy for this disease," stated Raul Rodriguez, president and CEO.
Motley Fool•2 months agoRigel Pharmaceuticals Inc (RIGL) Q1 2019 Earnings Call Transcript
RIGL earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 5.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Rigel: 1Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 11 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by ...
- PR Newswire•2 months ago
Rigel Announces First Quarter 2019 Financial Results and Provides Company Update
TAVALISSE® net product sales of $8.1 million on 1,019 bottles, a 10% increase quarter-over-quarter Total revenues of $12.6 million , including $4.6 million from collaborations Opened clinical trial sites ...
- PR Newswire•3 months ago
Rigel Announces Conference Call and Webcast to Report First Quarter 2019 Financial Results and Company Update
SOUTH SAN FRANCISCO, Calif. , April 30, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2019 financial results after market close on ...
- Simply Wall St.•3 months ago
If You Had Bought Rigel Pharmaceuticals (NASDAQ:RIGL) Stock A Year Ago, You'd Be Sitting On A 40% Loss, Today
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders should be happy to see the share price up 16% in the last quarter. But that is minimal compensation for the share price under-performance over the last year. After all...
- Motley Fool•3 months ago
Here's Why Rigel Pharmaceuticals Gained 17.3% in March
The pharma company announced full-year 2018 operating results.
- PR Newswire•4 months ago
Rigel Welcomes Jane Wasman to Board of Directors
SOUTH SAN FRANCISCO, Calif., March 26, 2019 /PRNewswire/ --Rigel Pharmaceuticals, Inc. (RIGL) today announced that it has appointed Jane Wasman to its board of directors. Ms. Wasman is a strategic leader with over 20 years of experience in the biopharma industry working with both large, multinational corporations and privately held start-ups. The wealth of strategic, operational and legal knowledge she brings to the company will be invaluable as we continue to expand our potential market opportunity," said Raul Rodriguez, president and CEO of Rigel.
- Simply Wall St.•4 months ago
Is Rigel Pharmaceuticals, Inc.’s (NASDAQ:RIGL) CEO Overpaid Relative To Its Peers?
Raul Rodriguez has been the CEO of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies ofRead More...
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of RIGL earnings conference call or presentation 28-Feb-19 10:00pm GMT
Q4 2018 Rigel Pharmaceuticals Inc Earnings Call
Motley Fool•5 months agoRigel Pharmaceuticals (RIGL) Q4 2018 Earnings Conference Call Transcript
RIGL earnings call for the period ending December 31, 2018.
- PR Newswire•5 months ago
Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
Fourth quarter total revenues of $37.9 million ; full year total revenues of $44.5 million Fourth quarter net product sales of $7.3 million ; full year net product sales of $13.9 million Conference call ...
- PR Newswire•5 months ago
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End Financial Results
SOUTH SAN FRANCISCO, Calif. , Feb. 21, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2018 financial results after market ...
